E-Abstract

  1. Home
  2. E-Science Station
  3. E-Abstract
JACC

Lots of interesting abstracts and cases were submitted for TCTAP 2025. Below are the accepted ones after a thorough review by our official reviewers. Don’t miss the opportunity to expand your knowledge and interact with authors as well as virtual participants by sharing your opinion in the comment section!

TCTAP A-001

Patients With a Small Annulus in the LANDMARK Trial - Early Outcomes With Three TAVI Valves

By Patrick Serruys, Akihiro Tobe, Niels van Royen, Ignacio Amat-Santos, Martin Hudec, Matjaz Bunc, Alexander Ijsselmuiden, Peep Laanmets, Daniel Unic, Bela Merkely, Renicus Hermanides, Vlasis Ninios, Marcin Protasiewicz, Benno Rensing, Pedro Martin, Fausto Feres, Manuel Almeida, Eric van Belle, Axel Linke, Alfonso Ielasi, Matteo Montorfano, Mark Webster, Konstantinos Toutouzas, Emmanuel Teiger, Francesco Bedogni, Michiel Voskuil, Manuel Pan, Oskar Angreas, Won-Keum Kim, Jurgen Rothe, Ivica Kristic, Vicente Peral, Mohamed Abdel-Wahab, Ashokkumar Thakkar, Udita Chandra, Marie-Claude Morice, Osama Soliman, Yoshinobu Onuma, Andreas Baumbach

Presenter

Patrick Serruys

Authors

Patrick Serruys1, Akihiro Tobe1, Niels van Royen2, Ignacio Amat-Santos3, Martin Hudec4, Matjaz Bunc5, Alexander Ijsselmuiden6, Peep Laanmets7, Daniel Unic8, Bela Merkely9, Renicus Hermanides10, Vlasis Ninios11, Marcin Protasiewicz12, Benno Rensing13, Pedro Martin14, Fausto Feres15, Manuel Almeida16, Eric van Belle17, Axel Linke18, Alfonso Ielasi19, Matteo Montorfano20, Mark Webster21, Konstantinos Toutouzas22, Emmanuel Teiger23, Francesco Bedogni24, Michiel Voskuil25, Manuel Pan26, Oskar Angreas27, Won-Keum Kim28, Jurgen Rothe29, Ivica Kristic30, Vicente Peral31, Mohamed Abdel-Wahab32, Ashokkumar Thakkar33, Udita Chandra33, Marie-Claude Morice34, Osama Soliman1, Yoshinobu Onuma1, Andreas Baumbach35

Affiliation

University of Galway, Ireland1, Radboud University Hospital, Netherlands2, Centro de Investigacion Biomedica en Red, Spain3, Middle-Slovak Institute of Cardiovascular Diseases, Slovak Republic4, University Medical Centre Ljubljana, Slovenia5, Amphia Hospital, Netherlands6, North Estonia Medical Centre, Estonia7, University Hospital Dubrava, Croatia8, Semmelweis University Heart and Vascular Centre, Hungary9, Isala Hospital, Netherlands10, European Interbalkan Medical Center, Greece11, Wrocław Medical University, Poland12, St Antonius Hospital, Netherlands13, University Hospital of Gran Canaria Dr Negr?n, Spain14, Instituto Dante Pazzanese, Brazil15, NOVA University, Portugal16, Lille University, France17, University of Technology Dresden, Germany18, IRCCS Galeazzi Sant’Ambrogio Hospital, Italy19, Vita-Salute San Raffaele University, Italy20, Auckland City Hospital, New Zealand21, Hippokration Hospital, Greece22, Henri-Mondor University Hospital, France23, San Donato Hospital, Italy24, University Medical Center Utrecht, Netherlands25, University Hospital Reina Sof?a, Spain26, Gothenburg University, Sweden27, University of Giessen and Marburg, Germany28, University Medical Center Freiburg, Germany29, University Hospital of Split, Croatia30, Son Espases University Hospital, Spain31, University Hospital Leipzig, Germany32, Meril Life Sciences Pvt. Ltd., India33, Cardiovascular European Research Center, France34, Queen Mary University of London, United Kingdom35
View Study Report
TCTAP A-001
Minimalist TAVR

Patients With a Small Annulus in the LANDMARK Trial - Early Outcomes With Three TAVI Valves

Patrick Serruys1, Akihiro Tobe1, Niels van Royen2, Ignacio Amat-Santos3, Martin Hudec4, Matjaz Bunc5, Alexander Ijsselmuiden6, Peep Laanmets7, Daniel Unic8, Bela Merkely9, Renicus Hermanides10, Vlasis Ninios11, Marcin Protasiewicz12, Benno Rensing13, Pedro Martin14, Fausto Feres15, Manuel Almeida16, Eric van Belle17, Axel Linke18, Alfonso Ielasi19, Matteo Montorfano20, Mark Webster21, Konstantinos Toutouzas22, Emmanuel Teiger23, Francesco Bedogni24, Michiel Voskuil25, Manuel Pan26, Oskar Angreas27, Won-Keum Kim28, Jurgen Rothe29, Ivica Kristic30, Vicente Peral31, Mohamed Abdel-Wahab32, Ashokkumar Thakkar33, Udita Chandra33, Marie-Claude Morice34, Osama Soliman1, Yoshinobu Onuma1, Andreas Baumbach35

University of Galway, Ireland1, Radboud University Hospital, Netherlands2, Centro de Investigacion Biomedica en Red, Spain3, Middle-Slovak Institute of Cardiovascular Diseases, Slovak Republic4, University Medical Centre Ljubljana, Slovenia5, Amphia Hospital, Netherlands6, North Estonia Medical Centre, Estonia7, University Hospital Dubrava, Croatia8, Semmelweis University Heart and Vascular Centre, Hungary9, Isala Hospital, Netherlands10, European Interbalkan Medical Center, Greece11, Wrocław Medical University, Poland12, St Antonius Hospital, Netherlands13, University Hospital of Gran Canaria Dr Negr?n, Spain14, Instituto Dante Pazzanese, Brazil15, NOVA University, Portugal16, Lille University, France17, University of Technology Dresden, Germany18, IRCCS Galeazzi Sant’Ambrogio Hospital, Italy19, Vita-Salute San Raffaele University, Italy20, Auckland City Hospital, New Zealand21, Hippokration Hospital, Greece22, Henri-Mondor University Hospital, France23, San Donato Hospital, Italy24, University Medical Center Utrecht, Netherlands25, University Hospital Reina Sof?a, Spain26, Gothenburg University, Sweden27, University of Giessen and Marburg, Germany28, University Medical Center Freiburg, Germany29, University Hospital of Split, Croatia30, Son Espases University Hospital, Spain31, University Hospital Leipzig, Germany32, Meril Life Sciences Pvt. Ltd., India33, Cardiovascular European Research Center, France34, Queen Mary University of London, United Kingdom35

Background

Among patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve implantation (TAVI), nearly one third have a small aortic annulus. These patients are at higher risk of prosthetic valve dysfunction. Recently, the SMART trial reported that the self-expanding Evolut series was superior to balloon-expandable Sapien series with respect to echocardiographic hemodynamic outcomes at one year. The Myval series is a novel balloon-expandable transcatheter heart valve (THV) whose clinical non-inferiority at 30 days compared to the Evolut and Sapien series was recently demonstrated in the LANDMARK trial. However, the performance of Myval series in patients with a small aortic annulus is unknown.

Methods

The LANDMARK trial is a randomized, non-inferiority trial conducted in 16 countries, which compares the safety and effectiveness between Myval THV series and contemporary THV series (Sapien and Evolut) in accordance with the third Valve Academic Research Consortium recommendations. The primary endpoint was a composite all-cause death, all stroke, bleeding (type 3 or 4), acute kidney injury stage 2-4, major vascular complication, moderate or severe prosthetic valve regurgitation (PVR), and permanent pacemaker implantation at 30 days. This sub-study compared the clinical and echocardiographic outcomes at 30 days in patients with a small aortic annulus (aortic valve annulus area ≦430 mm2).

Results

The results and conclusions of the BEST CLINICAL ABSTRACTS will be released after the presentation on April 25.

Conclusion

The results and conclusions of the BEST CLINICAL ABSTRACTS will be released after the presentation on April 25.

E-Science Station

ABOUT TCTAP
PROGRAM
E-SCIENCE STATION
NEWS
SPONSORSHIP
ATTENDANCE